The Pfizer Documents - July 2022 Update

磁链地址复制复制磁链成功

magnet:?xt=urn:btih:098BDF41DDB0E77FC3E6A05DAE59DC709F272ABE

如发现链接(DMCA)违规请在线举报

在线播放复制链接

磁链详情

文件数目：725个文件
文件大小：11.71 GB
收录时间：2023-01-28
访问次数：3
相关内容：Pfizer Documents July 2022 Update

文件meta

pd-production-070122/FDA-CBER-2021-5683-0225598 to -0282129_125742_S1_M5_c4591001-A-Supp-D-adfacevd.xpt
3.95 GB
pd-production-050222/FDA-CBER-2021-5683-0066701 to -0123167_125742_S1_M5_c4591001-A-D-adfacevd.xpt
3.85 GB
pd-production-060122/FDA-CBER-2021-5683-0142307 to -0149081_125742_S1_M5_c4591001-A-Supp-D-adcevd.xpt
425.98 MB
pd-production-050222/FDA-CBER-2021-5683-0059000 to -0065773_125742_S1_M5_c4591001-A-D-adcevd.xpt
394.37 MB
pd-production-060122/FDA-CBER-2021-5683-0149082 to -0158559_125742_S1_M5_c4591001-S-D-ce.xpt
368.08 MB
pd-production-060122/FDA-CBER-2021-5683-0196049 to -0205317_125742_S1_M5_c4591001-S-Supp-D-ce.xpt
361.39 MB
pd-production-070122/125742_S1_M5_5351_c4591001-interim-mth6-adverse-events.pdf
183.44 MB
pd-production-050222/FDA-CBER-2021-5683-0123168 to -0126026_125742_S1_M5_c4591001-A-D-adva.xpt
162.85 MB
pd-production-050222/125742_S1_M5_5351_bnt162-01-interim3-lab-measurements.pdf
91.06 MB
pd-production-070122/FDA-CBER-2021-5683-0286267 to -0296903_125742_S1_M5_c4591001-S-Supp-D-suppce.xpt
83.19 MB
pd-production-050222/125742_S1_M5_5351_c4591001-interim-mth6-randomization-sensitive.pdf
64.92 MB
pd-production-040122/125742_S1_M5_5351_c4591001-fa-interim-randomization-sensitive.pdf
59.43 MB
pd-production-070122/FDA-CBER-2021-5683-0296904 to -0307543_125742_S1_M5_c4591001-S-D-suppce.xpt
53.58 MB
pd-production-070122/FDA-CBER-2021-5683-0282366 to -0285643_125742_S1_M5_c4591001-S-D-mb.xpt
48.15 MB
pd-production-060122/FDA-CBER-2021-5683-0159487 to -0162689_125742_S1_M5_c4591001-S-D-ec.xpt
46.56 MB
pd-production-070122/FDA-CBER-2021-5683-0225100 to -0225597_125742_S1_M5_c4591001-A-D-adcm.xpt
46.4 MB
pd-production-060122/FDA-CBER-2021-5683-0162690 to -0165892_125742_S1_M5_c4591001-S-D-ex.xpt
44.73 MB
pd-production-060122/FDA-CBER-2021-5683-0205318 to -0208520_125742_S1_M5_c4591001-S-Supp-D-ex.xpt
44.73 MB
pd-production-050222/FDA-CBER-2021-5683-0065774 to -0066700_125742_S1_M5_c4591001-A-D-addv.xpt
43.54 MB
pd-production-050222/125742_S1_M5_5351_bnt162-01-interim3-report-body.pdf
41.63 MB
pd-production-060122/FDA-CBER-2021-5683-0208521 to -0216666_125742_S1_M5_c4591001-S-Supp-D-suppvs.xpt
39.16 MB
pd-production-060122/FDA-CBER-2021-5683-0187906 to -0196048_125742_S1_M5_c4591001-S-D-suppvs.xpt
39.15 MB
pd-production-030122/125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf
36.94 MB
pd-production-060122/125742_S1_M5_5351_c4591001-fa-interim-adverse-events.pdf
31.71 MB
pd-production-030122/125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf
31.31 MB
pd-production-060122/FDA-CBER-2021-5683-0165893 to -0168682_125742_S1_M5_c4591001-S-D-is.xpt
29.38 MB
pd-production-040122/125742_S1_M5_5351_c4591001-interim-mth6-demographics.pdf
27.77 MB
pd-production-040122/125742_S1_M5_5351_c4591001-fa-interim-demographics.pdf
27.74 MB
pd-production-060122/FDA-CBER-2021-5683-0174607 to -0178318_125742_S1_M5_c4591001-S-D-suppdv.xpt
23.37 MB
pd-production-060122/FDA-CBER-2021-5683-0182981 to -0187905_125742_S1_M5_c4591001-S-D-suppmh.xpt
21.61 MB
pd-production-070122/125742_S1_M5_5351_c4591001-fa-interim-narrative-sensitive.pdf
18.85 MB
pd-production-030122/125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf
17.43 MB
pd-production-060122/FDA-CBER-2021-5683-0171524 to -0174606_125742_S1_M5_c4591001-S-D-suppds.xpt
16.94 MB
pd-production-030122/125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf
15.7 MB
pd-production-070122/125742_S2_M5_5354_wi235284-protocol.pdf
15.5 MB
pd-production-120121/Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-B.pdf
13.78 MB
pd-production-060122/FDA-CBER-2021-5683-0169082 to -0171523_125742_S1_M5_c4591001-S-D-suppdm.xpt
13.7 MB
pd-production-013122/CRFs-for-site-1128.pdf
13.55 MB
pd-production-123021/CRFs-for-site-1081.pdf
13.2 MB
pd-production-030122/125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf
13 MB
pd-production-120121/Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-A.pdf
12.29 MB
pd-production-030122/125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf
12.02 MB
pd-production-050222/125742_S1_M5_5351_c4591001-interim-mth6-sponsor-signature.pdf
11.95 MB
pd-production-060122/FDA-CBER-2021-5683-0158560 to -0159486_125742_S1_M5_c4591001-S-D-dv.xpt
11.43 MB
pd-production-011822/CRFs-for-site-1096.pdf
11.28 MB
pd-production-060122/125742_S1_M5_5351_c4591001-interim-mth6-publications.pdf
11.18 MB
pd-production-070122/125742_S1_M5_5351_c4591001-interim-mth6-interlab-standard.pdf
10.87 MB
pd-production-050222/125742_S1_M5_5351_bnt162-01-interim3-protocol.pdf
10.46 MB
pd-production-040122/125742_S1_M5_5351_c4591001-fa-interim-publications.pdf
9.76 MB
pd-production-050222/125742_S1_M5_5351_bnt162-01-interim3-sample-crf.pdf
9.1 MB